PE20121509A1 - Compuestos de triazolopiridinas como inhibidores de quinasa mps-1 - Google Patents
Compuestos de triazolopiridinas como inhibidores de quinasa mps-1Info
- Publication number
- PE20121509A1 PE20121509A1 PE2012000742A PE2012000742A PE20121509A1 PE 20121509 A1 PE20121509 A1 PE 20121509A1 PE 2012000742 A PE2012000742 A PE 2012000742A PE 2012000742 A PE2012000742 A PE 2012000742A PE 20121509 A1 PE20121509 A1 PE 20121509A1
- Authority
- PE
- Peru
- Prior art keywords
- triazolo
- pyridin
- halo
- nitro
- phenyl
- Prior art date
Links
- 102100022681 40S ribosomal protein S27 Human genes 0.000 title abstract 2
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000008523 triazolopyridines Chemical class 0.000 title 1
- -1 HYDROXYL- Chemical class 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical compound [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 abstract 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075535A EP2343297A1 (en) | 2009-11-30 | 2009-11-30 | Triazolopyridines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121509A1 true PE20121509A1 (es) | 2012-11-18 |
Family
ID=42028156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000742A PE20121509A1 (es) | 2009-11-30 | 2010-11-17 | Compuestos de triazolopiridinas como inhibidores de quinasa mps-1 |
Country Status (36)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| CA2821817A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| US20130303532A1 (en) | 2010-12-17 | 2013-11-14 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| US20140135319A1 (en) | 2010-12-17 | 2014-05-15 | Bayer Intellectual Property Gmbh | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| JP5822944B2 (ja) | 2010-12-17 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン |
| CA2821827A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| EP2651950A1 (en) | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| US9388140B2 (en) | 2011-03-31 | 2016-07-12 | Bayer Intellectual Property Gmbh | Substituted benzimidazoles |
| JP5951750B2 (ja) | 2011-04-06 | 2016-07-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリジン類およびその中間体 |
| AU2012244859B2 (en) * | 2011-04-21 | 2017-06-08 | Bayer Intellectual Property Gmbh | Triazolopyridines |
| WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| CA2867061A1 (en) | 2012-03-14 | 2013-09-19 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| JP6238979B2 (ja) * | 2012-07-10 | 2017-11-29 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジンを調製する方法 |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US9682995B2 (en) | 2013-01-30 | 2017-06-20 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
| US9670202B2 (en) * | 2013-06-07 | 2017-06-06 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines |
| DK3008062T3 (en) | 2013-06-11 | 2017-06-12 | Bayer Pharma AG | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES |
| US20160128988A1 (en) | 2013-06-11 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| EP2980088A1 (en) | 2014-07-28 | 2016-02-03 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| WO2015155042A1 (en) | 2014-04-07 | 2015-10-15 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-e]indolizines |
| EP2977375A1 (en) | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP2977377A1 (en) | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP2977376A1 (en) | 2014-07-25 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| US11208696B2 (en) | 2015-04-17 | 2021-12-28 | Netherlands Translational Research Center B.V. | Prognostic biomarkers for TTK inhibitor chemotherapy |
| KR101686411B1 (ko) * | 2015-12-28 | 2016-12-14 | 한국원자력의학원 | 피리딘계 유도체를 포함하는 암 예방 또는 치료용 조성물 |
| CN107641118B (zh) * | 2016-07-22 | 2020-11-06 | 爱科诺生物医药股份有限公司 | 具有细胞坏死抑制活性的化合物及其组合物和应用 |
| EP3492500B1 (en) | 2017-12-01 | 2023-09-20 | Daikin Industries, Ltd. | Use of a crosslinked product of a fluorine-containing amorphous elastomer |
| EP3877371A4 (en) * | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES USED AS JANUS KINASE 2 INHIBITORS AND ASSOCIATED USES |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| BR112022022409A2 (pt) | 2020-05-06 | 2023-02-07 | Ajax Therapeutics Inc | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2022178340A2 (en) * | 2021-02-22 | 2022-08-25 | Orgenesis Inc. | Pharmaceutical compositions comprising ranpirnase |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| US11970494B2 (en) | 2021-11-09 | 2024-04-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| EP1646382A4 (en) | 2003-06-30 | 2010-07-21 | Hif Bio Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| JP2008515874A (ja) | 2004-10-07 | 2008-05-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌薬 |
| WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| NZ573015A (en) | 2006-05-31 | 2010-11-26 | Galapagos Nv | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
| MX2009002171A (es) | 2006-08-30 | 2009-05-28 | Cellzome Ltd | Derivados de triazol como inhibidores de cinasas. |
| AU2008277628B2 (en) * | 2007-07-18 | 2012-03-15 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| CN103298814A (zh) * | 2007-08-23 | 2013-09-11 | 阿斯利康(瑞典)有限公司 | 作为治疗增殖性疾病的ttk/mps1抑制剂的2-苯胺基嘌呤-8-酮 |
| KR20100075881A (ko) * | 2007-08-31 | 2010-07-05 | 메르크 세로노 에스. 에이. | 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도 |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2009068482A1 (en) | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
| WO2010092015A1 (en) | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
| CA2751517A1 (en) * | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| EP2424537B1 (en) | 2009-04-29 | 2015-07-08 | Bayer Intellectual Property GmbH | Substituted imidazoquinoxalines |
| EP2473498A1 (en) | 2009-09-04 | 2012-07-11 | Bayer Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| US9145399B2 (en) | 2010-01-15 | 2015-09-29 | Janssen Pharmaceuticals, Inc. | Substituted bicyclic triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
-
2009
- 2009-11-30 EP EP09075535A patent/EP2343297A1/en not_active Withdrawn
-
2010
- 2010-11-17 MY MYPI2012002378A patent/MY160325A/en unknown
- 2010-11-17 RS RS20140646A patent/RS53670B1/sr unknown
- 2010-11-17 MX MX2012006252A patent/MX2012006252A/es active IP Right Grant
- 2010-11-17 NZ NZ600229A patent/NZ600229A/en not_active IP Right Cessation
- 2010-11-17 EP EP10787274.9A patent/EP2507235B1/en active Active
- 2010-11-17 AU AU2010324155A patent/AU2010324155B2/en not_active Ceased
- 2010-11-17 PL PL10787274T patent/PL2507235T3/pl unknown
- 2010-11-17 HR HRP20141093AT patent/HRP20141093T1/hr unknown
- 2010-11-17 PT PT107872749T patent/PT2507235E/pt unknown
- 2010-11-17 EA EA201200794A patent/EA022353B1/ru not_active IP Right Cessation
- 2010-11-17 BR BR112012012906A patent/BR112012012906A2/pt not_active IP Right Cessation
- 2010-11-17 CU CU2012000084A patent/CU24100B1/es active IP Right Grant
- 2010-11-17 SI SI201030810T patent/SI2507235T1/sl unknown
- 2010-11-17 PH PH1/2012/501055A patent/PH12012501055A1/en unknown
- 2010-11-17 DK DK10787274.9T patent/DK2507235T3/en active
- 2010-11-17 KR KR1020127016940A patent/KR20120115290A/ko not_active Ceased
- 2010-11-17 JP JP2012541336A patent/JP5805653B2/ja not_active Expired - Fee Related
- 2010-11-17 UA UAA201207609A patent/UA108486C2/uk unknown
- 2010-11-17 CA CA2781915A patent/CA2781915A1/en not_active Abandoned
- 2010-11-17 CN CN201080061524.1A patent/CN102762557B/zh not_active Expired - Fee Related
- 2010-11-17 PE PE2012000742A patent/PE20121509A1/es not_active Application Discontinuation
- 2010-11-17 US US13/512,701 patent/US9676766B2/en not_active Expired - Fee Related
- 2010-11-17 ES ES10787274.9T patent/ES2525069T3/es active Active
- 2010-11-17 WO PCT/EP2010/006994 patent/WO2011063908A1/en not_active Ceased
- 2010-11-30 AR ARP100104406A patent/AR079166A1/es unknown
-
2012
- 2012-05-13 IL IL219750A patent/IL219750A/en not_active IP Right Cessation
- 2012-05-24 ZA ZA2012/03806A patent/ZA201203806B/en unknown
- 2012-05-25 TN TNP2012000265A patent/TN2012000265A1/en unknown
- 2012-05-28 MA MA34899A patent/MA33768B1/fr unknown
- 2012-05-30 DO DO2012000150A patent/DOP2012000150A/es unknown
- 2012-05-30 EC ECSP12011935 patent/ECSP12011935A/es unknown
- 2012-05-30 CR CR20120295A patent/CR20120295A/es unknown
- 2012-05-30 GT GT201200165A patent/GT201200165A/es unknown
- 2012-05-30 HN HN2012001162A patent/HN2012001162A/es unknown
- 2012-05-30 CL CL2012001391A patent/CL2012001391A1/es unknown
-
2014
- 2014-11-21 CY CY20141100970T patent/CY1115866T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121509A1 (es) | Compuestos de triazolopiridinas como inhibidores de quinasa mps-1 | |
| PE20141050A1 (es) | Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina | |
| PE20070855A1 (es) | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| AR054799A1 (es) | Derivados de oxindol | |
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| PE20130611A1 (es) | Triazolopiridinas sustituidas | |
| PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| NO20070731L (no) | Heterocykliske forbindelser. | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| PE20110828A1 (es) | Compuestos de pirazolopirimidina como inhibidores de jak | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| PE20120305A1 (es) | Compuestos heterociclicos derivados de benzotiazol y tetrahidroquinolina como inhbidores de bcl-2 y bcl-xl | |
| WO2008057775A3 (en) | Heterocyclic amide compounds useful as kinase inhibitors | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| NZ591449A (en) | Picolinamide derivatives as kinase inhibitors | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| NO20092692L (no) | MAPK/ERK kinaseinhibitorer | |
| SA520411638B1 (ar) | Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| MY160785A (en) | Manufacturing process for pyrimidine derivatives | |
| PE20070854A1 (es) | Compuestos heterociclos como agonistas del receptor de acido nicotinico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |